eXoZymes, Inc.
eXoZymes, Inc. (EXOZ) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EXOZ · as of Sep 30, 2025
Ownership Breakdown
6
Institutional Holders
▼ 3 vs Q2
$880,361
Total Inst. Value
▲ $152,919 vs Q2
8.48M
Shares Outstanding
freeFloat 25.75%
59,923
13F Shares Held
▼ 15,459 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EXOZ largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 9 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 26.0K | 30.98% | 30.98% | $383.22M | Nov 7, 2025 | ▲ 2.8K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 23.1K | 27.50% | 27.50% | $340.18M | Nov 12, 2025 | ▲ 2.5K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 5.0K | 5.94% | 5.94% | $71.92M | Nov 12, 2025 | ▲ 144 |
UBS GROUP AG biological products, (no diagnostic substances) | 4.6K | 5.51% | 5.51% | $66.67M | Nov 13, 2025 | ▼ 393 |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.3K | 1.49% | 1.49% | $18.04M | May 27, 2026 | — held |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 23 | 0.03% | 0.03% | $332,000 | Feb 3, 2026 | ▼ 13 |
RAYMOND JAMES FINANCIAL INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
TOWER RESEARCH CAPITAL LLC (TRC) biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
3
Increased
+5.4K shares0
New Positions
first time holders2
Decreased
−406 shares3
Sold Out
fully exitedNet shares change (top 50)
+5.0K
+5.4K / −406
Net new holders
-2
0 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EXOZ insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
2
Sell transactions
3.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Korman Tyler Paz Chief Scientific Officer | Apr 8, 2026 | Sale | 750 | $10.04 | $7.5K | 729.9K | Form 4 ↗ |
Korman Tyler Paz Chief Scientific Officer | Apr 9, 2026 | Sale | 750 | $10.53 | $7.9K | 729.1K | Form 4 ↗ |
Perriman Damien Alan Chief Commercial Officer | Apr 1, 2026 | Award | 146,437 | $9.49 | $1.39M | 146.4K | Form 4 ↗ |
Perriman Damien Alan Chief Commercial Officer | Apr 1, 2026 | Award | 62,759 | — | — | 62.8K | Form 4 ↗ |
Perriman Damien Alan Chief Commercial Officer | Apr 1, 2026 | Award | 8,887 | $8.44 | $75.0K | 0 | Form 4 ↗ |
Opgenorth Paul Hideo Vice President, Development | Apr 1, 2026 | Award | 3,999 | $8.44 | $33.8K | 645.1K | Form 4 ↗ |
Nawaz Fouad Vice President- Finance | Apr 1, 2026 | Award | 5,999 | $8.44 | $50.6K | 9.5K | Form 4 ↗ |
Korman Tyler Paz Chief Scientific Officer | Apr 1, 2026 | Award | 5,332 | $8.44 | $45.0K | 730.6K | Form 4 ↗ |
Heltzen Michael Chief Executive Officer | Jul 2, 2025 | Purchase | 1,040 | $10.22 | $10.6K | 10.6K | Form 4 ↗ |
Heltzen Michael Chief Executive Officer | Jun 17, 2025 | Award | 235,817 | $12.40 | $2.92M | 235.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
eXoZymes, Inc. (EXOZ) is primarily owned by institutional investors, who hold approximately 0.7% of total shares outstanding. Company insiders own approximately 74.25%, while retail and public investors account for the remaining 25.04%.
The largest institutional shareholder of eXoZymes, Inc. is VANGUARD GROUP INC, holding approximately 25,981 shares — equal to 30.98% of outstanding shares — as of September 30, 2025.
A total of 6 institutional investors currently hold EXOZ stock, with a combined institutional value of approximately $880,361 as of the most recent 13F filing period.
Frequently asked questions
EXOZ ownershipeXoZymes, Inc. (EXOZ) is primarily owned by institutional investors, who hold approximately 0.7% of shares. The largest shareholder is VANGUARD GROUP INC with a 30.98% stake. Company insiders hold 74.25%. Data sourced from SEC Form 13F as of September 30, 2025.